Juno Therapeutics to highlight CD19- and BCMA-targeted CAR T therapy at ASH 2017

Juno Therapeutics (JUNO) announced that 15 abstracts detailing updated clinical and preclinical results from the company and its collaborators will be presented at the 59th American Society of Hematology Annual Meeting.

Senior executives will also review results and provide an update on Juno’s clinical development program at an analyst and investor event, which will also be available via webcast.

Updated data from the TRANSCEND study of JCAR017 in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma will be presented by Principal Investigator Jeremy Abramson, M.D., of the Massachusetts General Hospital, on December 11.

The presentation will include new information on enrollment, safety, response rates, duration of response, and overall survival.

The primary TRANSCEND abstract released today includes data from the core analysis group, which includes patients that represent the population that Juno is studying in the ongoing pivotal cohort. The core group includes patients with DLBCL who are ECOG Performance Status 0-1.

These patients represent a highly refractory population based on some key factors that are associated with a poor prognosis including an older age, having a double or triple hit, and being chemorefractory. Topline data from the abstract for both dose levels for the core group as of a data cutoff date of July 7, 2017 included: Dose level 2, the dose in the pivotal cohort for the TRANSCEND study, showed a 3 month overall response rate of 80% and a 3 month complete response rate of 73% in the core group.

Data support a dose response relationship. Dose level 1 showed 3 month ORR of 52% and a 3 month CR rate of 33%. Across both doses in the core group, the best overall response was 84% and the best overall CR rate was 61%.

There was no increase in cytokine release syndrome and neurotoxicity rates associated with the higher dose or between the full and core groups. Across doses in the full group, 1% experienced severe CRS and 14% experienced severe NT. 30% had any grade CRS and 20% had any grade NT. 64% had no CRS or NT.

The most common treatment-emergent adverse events other than CRS and NT that occurred at greater than or equal to25% in the full group included neutropenia, fatigue, thrombocytopenia, and anemia.

JUNO closed at $44.91.


STOCKWINNERS

To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners. 

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.